BACKGROUND: Radiotherapy with concomitant and adjuvant temozolomide (six cycles) is the standard treatment after surgery in glioblastoma patients. Few studies have assessed the impact of additional cycles of temozolomide on survival. PATIENTS AND METHODS: We conducted a bi-centric retrospective study comparing survival and toxicity according to the number of cycles of adjuvant temozolomide. RESULTS: Fifty-eight patients were included. All patients received radiotherapy with concomitant temozolomide. Thirty-eight patients received six cycles, while 20 received nine or more (median=14) cycles. The risk of recurrence was significantly higher in the group receiving six cycles compared to the other group. Prolonged treatment improved progression-free survival (p=0.03) and overall survival (p=0.01) in multivariate analysis without a significant increase in toxicity. CONCLUSION: Prolonged administration of temozolomide seems to improve progression-free and overall survival, without increased toxicity. Prospective studies in larger populations are needed to better-define the population to whom it can be proposed and its optimal duration.
BACKGROUND: Radiotherapy with concomitant and adjuvant temozolomide (six cycles) is the standard treatment after surgery in glioblastomapatients. Few studies have assessed the impact of additional cycles of temozolomide on survival. PATIENTS AND METHODS: We conducted a bi-centric retrospective study comparing survival and toxicity according to the number of cycles of adjuvant temozolomide. RESULTS: Fifty-eight patients were included. All patients received radiotherapy with concomitant temozolomide. Thirty-eight patients received six cycles, while 20 received nine or more (median=14) cycles. The risk of recurrence was significantly higher in the group receiving six cycles compared to the other group. Prolonged treatment improved progression-free survival (p=0.03) and overall survival (p=0.01) in multivariate analysis without a significant increase in toxicity. CONCLUSION: Prolonged administration of temozolomide seems to improve progression-free and overall survival, without increased toxicity. Prospective studies in larger populations are needed to better-define the population to whom it can be proposed and its optimal duration.
Authors: Marco Skardelly; Elena Dangel; Julia Gohde; Susan Noell; Felix Behling; Guilherme Lepski; Christian Borchers; Marilin Koch; Jens Schittenhelm; Sotirios Bisdas; Aline Naumann; Frank Paulsen; Daniel Zips; Ulrike von Hehn; Rainer Ritz; Marcos Soares Tatagiba; Ghazaleh Tabatabai Journal: Oncologist Date: 2017-03-30
Authors: Alia M Attia; Hanan A Eltybe; Mayada F Sedik; Ahmed Mubarak Hefni; Marwa I Abdelgawad; Ashraf Farrag; Abdelhakeem A Essa; Mohamed M El-Barody; Noha M Attia Journal: Am J Cancer Res Date: 2022-01-15 Impact factor: 6.166
Authors: Alexander J Neuwelt; Tam M Nguyen; Rongwei Fu; Joseph Bubalo; Rose Marie Tyson; Cynthia Lacy; Seymur Gahramanov; Morad Nasseri; Penelope D Barnes; Edward A Neuwelt Journal: CNS Oncol Date: 2014-07